Literature DB >> 9226746

Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study.

Y Noda1, A Mori, L Packer.   

Abstract

The role of reactive oxygen species in diabetes and its complications are well known. Two therapeutic agents commonly used in the treatment of diabetes are the sulfonylureas, gliclazide and glibenclamide. These drugs effectively reduce blood sugar in non-insulin dependent diabetes millitus by augmenting insulin release. Gliclazide is known to be a general free radical scavenger as demonstrated by inhibition of o-dianisidine photo-oxidation. In this study, the effects of gliclazide and glibenclamide on free radicals were examined in vitro, using electron spin resonance (ESR) spectroscopy. Superoxide radical (O2.-) generated from hypoxanthine-xanthine oxidase system, or hydroxyl radical (.OH) generated by the Fenton reaction, were analyzed as spin adducts of 5,5-dimethyl-1-pyrroline-N-oxide (DMPO). NO was generated from 1-hydroxy-2-oxo-3-(N-3-methyl-3-aminopropyl)-3-methyl-1-triazene (NOC-7), and analyzed by 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl (carboxy-PTI) produced from the reaction between 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (carboxy-PTIO) and NO. Gliclazide scavenged O2.-, .OH and NO in a dose-dependent manner whereas glibenclamide was without effect. These findings suggest that gliclazide is not only effective in reducing blood sugar but also may be beneficial by inhibition of lipid and protein denaturation, which leads to the development of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226746

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  8 in total

1.  Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-28       Impact factor: 2.441

2.  Pinacidil, a KATP channel opener, stimulates cardiac Na+/Ca2+ exchanger function through the NO/cGMP/PKG signaling pathway in guinea pig cardiac ventricular myocytes.

Authors:  Keisuke Iguchi; Masao Saotome; Kanna Yamashita; Prottoy Hasan; Miyuki Sasaki; Yuichiro Maekawa; Yasuhide Watanabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-03-27       Impact factor: 3.000

3.  Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced by streptozosin.

Authors:  Harun Alp; Sefer Varol; Muhammet Murat Celik; Murat Altas; Osman Evliyaoglu; Orhan Tokgoz; Mehmet Halis Tanrıverdi; Ertugrul Uzar
Journal:  Exp Diabetes Res       Date:  2012-01-16

4.  Gliclazide does not fully prevent 2-deoxy-D-ribose-induced oxidative damage because it does not restore glutathione content in a pancreatic β-cell line.

Authors:  Gwanpyo Koh; Min-Kyoung Kim; Eun-Jin Yang; Dae-Ho Lee
Journal:  Oxid Med Cell Longev       Date:  2012-01-19       Impact factor: 6.543

5.  Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.

Authors:  Akira Kubota; Daisuke Yabe; Akira Kanamori; Akira Kuroe; Nobuo Takahashi; Tatsuhiko Saito; Ikuro Matsuba; Koichiro Nabe; Takeshi Kurose; Yutaka Seino
Journal:  J Diabetes Investig       Date:  2014-02-11       Impact factor: 4.232

6.  Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study.

Authors:  Yu-Jih Su; Jing-Yang Huang; Cong-Qiu Chu; James Cheng-Chung Wei
Journal:  Front Med (Lausanne)       Date:  2022-07-27

7.  Correlation of oxidative stress parameters and inflammatory markers in tunisian coronary artery disease patients.

Authors:  Azza Dandana; Imen Gammoudi; Salima Ferchichi; Hinda Chahed; Hlima Ben Limam; Faouzi Addad; Abdelhedi Miled
Journal:  Int J Biomed Sci       Date:  2011-03

8.  Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Paul J Fawcett; Svetlana Golocorbin-Kon; Ivan Mikov; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.